Bayer’s compulsory licence appeal date set

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Bayer’s compulsory licence appeal date set

India’s Intellectual Property Appellate Board will hear Bayer’s appeal of a controversial compulsory licence ruling on August 21 in Chennai, according to Pharmabiz.com

The Controller of Patents issued a compulsory licence in March to domestic generic drug maker Natco for the cancer treatment drug sorafenib.

The German pharmaceutical company filed its appeal with the country’s Intellectual Property Appellate Board on May 4.

The compulsory licence is in force for the remaining term of the patent licence and requires Natco to pay a royalty rate of 6% of net sales of the drug.

The Controller said in March that he was granting the compulsory licence on the grounds (a) that the reasonable requirements of the public with respect to the patented invention had not been satisfied, (b) that the patented invention was not available to the public at a reasonably affordable price, and (c) that the patented invention was not being worked in India.

Bayer attacked the Patent Controller’s ruling in a statement, saying that it “damages the international patent system and endangers pharmaceutical research”.

For more of Managing IP’s coverage of the case, click here and here. More details are available on Pharmabiz.com.

more from across site and SHARED ros bottom lb

More from across our site

In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Yonatan Drori, attorney at Drori-Stav IP in Israel, explains why foreign counsel must treat Israel’s patent disclosure requirements as an ongoing obligation, rather than a one-off formality
From Japan to Southeast Asia, domestic and regional firms picked up some of the biggest prizes, while key foreign players maintained momentum
Earlier this month, Managing IP had exclusively reported that the French arm of Taylor Wessing was minded to pull out of the deal
Our latest podcast examines how Weil’s IP practice evolved, where its practitioners could (and will) go next, and which firms and markets stand to benefit from the redistribution of talent
Gift this article